SCHEMBL108456

SCHEMBL108456

N=C(CCC(=O)OC(=O)C(O)C(O)C(=O)O)OC(=O)C(O)C(O)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL94759 0.88 TSHR (0.48) TSHR
SCHEMBL27625179 0.86 TSHR (0.46) TSHR
SCHEMBL7035397 0.86 TSHR (0.46) TSHR
SCHEMBL27314245 0.82 TSHR (0.42) TSHR
Cadaverine Tartrate SCHEMBL8321372 0.82 TSHR (0.42) TSHR
SCHEMBL28182002 0.81 TSHR (0.40) TSHR
SCHEMBL1864896 0.80 TSHR (0.43) TSHR
Cadaverine Tartrate SCHEMBL28179966 0.79 TSHR (0.39) TSHR
SCHEMBL23069532 0.77 ALDH1A1 (0.54) TSHR
Ammonia Solution, Strong SCHEMBL27726717 0.77 TSHR (0.40) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200080122-A1 Cleavable Nucleotide Analogs and Uses Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2020-03-12 US claimed
US-20260077088-A1 SELF-DEGRADING ENZYME LOADED BIOLOGICALLY DERIVED PARTICLES CRANNMED LIMITED (IE) 2026-03-19 US disclosed
EP-4583839-A1 SELF-DEGRADING ENZYME LOADED BIOLOGICALLY DERIVED PARTICLES Crannmed Limited (IE) 2025-07-16 EP disclosed
WO-2025137256-A1 POLYOXAZOLINE-CARBOHYDRATE-LIPID CONJUGATES WU NIAN (US) 2025-06-26 WO disclosed
US-20250099480-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANDIDA AURIS IN BLOOD CORMEDIX INC (US) 2025-03-27 US disclosed
US-12016865-B2 Methods and pharmaceutical compositions for treating candida auris in blood CORMEDIX INC. (US) 2024-06-25 US disclosed
WO-2024052780-A1 SELF-DEGRADING ENZYME LOADED BIOLOGICALLY DERIVED PARTICLES CRANNMED LIMITED (IE) 2024-03-14 WO disclosed
US-11712419-B2 Liposome formulations OPKO PHARMACEUTICALS, LLC (US) 2023-08-01 US disclosed
US-11458199-B2 Liposome formulations OPKO PHARMACEUTICALS, LLC (US) 2022-10-04 US disclosed
EP-2887958-B1 LIPOSOME FORMULATIONS OPKO PHARMACEUTICALS LLC (US) 2021-05-19 EP disclosed
US-20120202890-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES WU NIAN (US) 2012-08-09 US disclosed
US-20120202979-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES LIPOSEUTICALS, INC. 2012-08-09 US disclosed
WO-2012057628-A2 CROSS-LINKED POLYMERS AND IMPLANTS DERIVED FROM ELECTROPHILICALLY ACTIVATED POLYOXAZOLINE BENDER ANALYTICAL HOLDING B.V. (NL) 2012-05-03 WO disclosed
EP-2424971-A1 METHODS AND COMPOSITIONS FOR MEASURING HIGH AFFINITY INTERACTIONS WITH KINETIC IMAGING OF SINGLE MOLECULE INTERACTION (KISMI) University of Utah Research Foundation (US) 2012-03-07 EP disclosed
WO-2011139343-A2 AMINO ACID LINKED PEG-LIPID CONJUGATES WU NIAN (US) 2011-11-10 WO disclosed
WO-2010127247-A1 METHODS AND COMPOSITIONS FOR MEASURING HIGH AFFINITY INTERACTIONS WITH KINETIC IMAGING OF SINGLE MOLECULE INTERACTION (KISMI) UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2010-11-04 WO disclosed
US-20100076209-A1 PEG-lipid conjugates for liposomes and drug delivery BIOZONE LABORATORIES INC. 2010-03-25 US disclosed
US-5045312-A Complexing BURROUGHS WELLCOME CO. (US) 1991-09-03 US disclosed
EP-0377649-A1 HALOGENATED SURFACE WITH REDUCED PROTEIN INTERACTION. HEWLETT PACKARD CO (US) 1990-07-18 EP disclosed
WO-1989012225-A1 HALOGENATED SURFACE WITH REDUCED PROTEIN INTERACTION HEWLETT-PACKARD COMPANY (US) 1989-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076209-A1 PEG-lipid conjugates for liposomes and drug delivery DAGLA, DAGLB, DGKG TSHR 2520/4885
US-20200080122-A1 Cleavable Nucleotide Analogs and Uses Thereof TYMP, DUT, NT5C3B TSHR 2802/4885
US-20120202890-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES LIPC, FUT6, UGCG TSHR 3962/4885
US-20260077088-A1 SELF-DEGRADING ENZYME LOADED BIOLOGICALLY DERIVED PARTICLES MMP2, PLG, PMM2 TSHR 1647/4885
US-20120202979-A1 POLYMER-CARBOHYDRATE-LIPID CONJUGATES LIPC, FUT6, UGCG TSHR 3962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.